Eli Lilly reports results from Covid-19 phase 2 antibody drug trial
Tests have shown that the antibody-based drug reduces the need for hospitalization in patients with moderate disease
Pharmaceutical company Eli Lilly and Co on Wednesday reported interim test data that showed experimental antibody treatments reduce hospital admissions and emergency department visits for patients with moderate COVID-19.
The trials tested three different doses of LY-CoV555, an antibody-based drug that is designed to neutralize the virus.
Analysts Expect Antibody Treatment May Help Some Patients As Longer Vaccine Development Continues.
Many companies, including Regeneron Pharmaceuticals Inc and Vir Biotechnology, are also testing antibody-based drugs..
Of the 302 patients who received three different doses of LY-CoV555, only five, or 1.7 percent, were hospitalized or admitted to the hospital. Among those receiving a placebo, 9 out of 150 people needed medical attention, which is 6 percent.
According to Lilly, only an average dose of 2,800 milligrams met the study’s primary goal of reducing viral load 11 days after treatment..
No serious side effects reported.
The company plans to publish the results of the interim analysis in a peer-reviewed scientific journal and discuss the appropriate next steps with global regulators.
Rhode Island Hospital’s Outpatient Dialysis Program Eli Lilly and Regeneron have received regulatory approval but are not widely used yet Dialysis…
Eli Lilly CEO explains the supply chain of Covid-19 antibody drug Government to purchase 300,000 doses of an experimental antibody drug The US government…
Drug that was tested for use against Ebola could treat COVID-19 The results of the study will be announced by May 1 this year. A US biotech company said…
In the absence of a vaccine, treatment of COVID-19 with antibodies is considered a promising technique WASHINGTON – Doctors are trying to grow the human…